These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16356575)

  • 21. A pharmacological comparison of the cloned frog and human mu opioid receptors reveals differences in opioid affinity and function.
    Brasel CM; Sawyer GW; Stevens CW
    Eur J Pharmacol; 2008 Dec; 599(1-3):36-43. PubMed ID: 18930720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mu opioid receptor mutant, T394A, abolishes opioid-mediated adenylyl cyclase superactivation.
    Wang H; Guang W; Barbier E; Shapiro P; Wang JB
    Neuroreport; 2007 Dec; 18(18):1969-73. PubMed ID: 18007196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
    Désormeaux A; Bergeron MG
    Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
    Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
    Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel.
    Luo LM; Huang Y; Zhao BX; Zhao X; Duan Y; Du R; Yu KF; Song P; Zhao Y; Zhang X; Zhang Q
    Biomaterials; 2013 Jan; 34(4):1102-14. PubMed ID: 23127332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation.
    Nallamothu R; Wood GC; Pattillo CB; Scott RC; Kiani MF; Moore BM; Thoma LA
    AAPS PharmSciTech; 2006 Apr; 7(2):E32. PubMed ID: 16796350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies.
    Xie Y; Ye L; Zhang X; Cui W; Lou J; Nagai T; Hou X
    J Control Release; 2005 Jun; 105(1-2):106-19. PubMed ID: 15893839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted cellular delivery of quantum dots loaded on and in biotinylated liposomes.
    Sigot V; Arndt-Jovin DJ; Jovin TM
    Bioconjug Chem; 2010 Aug; 21(8):1465-72. PubMed ID: 20715851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
    Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
    PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X; Ding L; Xu Y; Wang Y; Ping Q
    Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biochemical demonstration of mu-opioid receptor association with Gsalpha: enhancement following morphine exposure.
    Chakrabarti S; Regec A; Gintzler AR
    Brain Res Mol Brain Res; 2005 Apr; 135(1-2):217-24. PubMed ID: 15857684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies.
    Dagar S; Krishnadas A; Rubinstein I; Blend MJ; Onyüksel H
    J Control Release; 2003 Aug; 91(1-2):123-33. PubMed ID: 12932644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding and internalization of fluorescent opioid peptide conjugates in living cells.
    Arttamangkul S; Alvarez-Maubecin V; Thomas G; Williams JT; Grandy DK
    Mol Pharmacol; 2000 Dec; 58(6):1570-80. PubMed ID: 11093798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells.
    Sauer I; Dunay IR; Weisgraber K; Bienert M; Dathe M
    Biochemistry; 2005 Feb; 44(6):2021-9. PubMed ID: 15697227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci.
    Bakker-Woudenberg IA
    Int J Antimicrob Agents; 2002 Apr; 19(4):299-311. PubMed ID: 11978501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of tumor-selective targeting by basic fibroblast growth factor-binding peptide grafted PEGylated liposomes.
    Terada T; Mizobata M; Kawakami S; Yamashita F; Hashida M
    J Control Release; 2007 Jun; 119(3):262-70. PubMed ID: 17467100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, Biological Evaluation, and Utility of Fluorescent Ligands Targeting the μ-Opioid Receptor.
    Schembri LS; Stoddart LA; Briddon SJ; Kellam B; Canals M; Graham B; Scammells PJ
    J Med Chem; 2015 Dec; 58(24):9754-67. PubMed ID: 26632862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposomes for intravenous drug targeting: design and applications.
    Metselaar JM; Mastrobattista E; Storm G
    Mini Rev Med Chem; 2002 Aug; 2(4):319-29. PubMed ID: 12370053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.
    Neilan CL; Janvey AJ; Bolan E; Berezowska I; Nguyen TM; Schiller PW; Pasternak GW
    J Pharmacol Exp Ther; 2003 Aug; 306(2):430-6. PubMed ID: 12663687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.